A phase II study of erlotinib (Tarceva) in patients with muscle-invasive bladder cancer undergoing radical cystectomy
Phase of Trial: Phase II
Latest Information Update: 21 Jul 2017
At a glance
- Drugs Erlotinib (Primary)
- Indications Bladder cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 19 May 2017 Status changed from active, no longer recruiting to completed.
- 22 Nov 2016 Planned End Date changed from 1 Aug 2016 to 1 Aug 2018.
- 10 Dec 2015 Planned End Date changed from 1 Aug 2015 to 1 Aug 2016 as reported by ClinicalTrials.gov record.